ADCT.US ADC Therapeutics SA

Healthcare Biotechnology USA Stocks
1.41 USD
Close of Nov 12, 2026
0.7796 4.98
Market cap
USD 198M
P/E
-
P/B
3.42x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ADCT.US undervalued?

Graham number

The Graham number of ADC Therapeutics SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ADC Therapeutics SA fundamental analysis

No fundamental analysis for ADC Therapeutics SA yet.

ADC Therapeutics SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ADC Therapeutics SA

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or …

Full company profile